Skip to content

Merck’s 2025 Revenue Forecast: A 5% Miss from Expectations

Merck has projected its 2025 revenue to be between $64.1 billion and $65.6 billion, which is lower than the $67.31 billion analysts anticipated. This shortfall is attributed to a temporary halt in Gardasil vaccine shipments to China, starting in February and extending through at least mid-2025. Gardasil, which prevents cancer from HPV, saw a 17% sales drop to $1.55 billion in the fourth quarter of 2024, slightly under the expected $1.58 billion. Despite this, Merck’s overall fourth-quarter performance was strong, with total revenue reaching $15.62 billion, a 7% increase from the previous year. Keytruda, Merck’s top-selling cancer drug, generated $7.84 billion in sales, surpassing the $7.63 billion forecast. However, sales of Januvia, a diabetes treatment, fell by 38% to $487 million due to pricing issues and competition from generics. Meanwhile, the animal health division saw a 9% sales increase to nearly $1.4 billion.

Source: www.cnbc.com

Related Videos